Rituxan Labeling Updated With Follow-Up Treatment Info for Patients With GPA/MPA

Rituxan Labeling Updated With Follow-Up Treatment Info for Patients With GPA/MPA

The FDA has approved updated labeling for Rituxan to include information on follow up treatment for patients with GPA and MPA who have achieved disease control with induction therapy.

Giant Cell Arteritis: Examining Challenges in Diagnosis and Treatment

Giant Cell Arteritis: Examining Challenges in Diagnosis and Treatment

Improved biomarkers are needed to monitor disease activity effectively in giant cell arteritis.

Improved Immune Response to Pneumococcal Vaccine in ANCA-Associated Vasculitis

Improved Immune Response to Pneumococcal Vaccine in ANCA-Associated Vasculitis

Suppressing cytomegalovirus may improve the immune response to a T cell-dependent pneumococcal vaccination in patients experiencing ANCA-associated vasculitis.

Granulomatosis With Polyangiitis Linked to Altered Nasal Microbial Composition

Granulomatosis With Polyangiitis Linked to Altered Nasal Microbial Composition

Granulomatosis with polyangiitis was associated with an altered nasal microbial composition at both the bacterial and the fungal levels.

Examining Risk for Severe Infection in Rituximab-Treated AAV

Examining Risk for Severe Infection in Rituximab-Treated AAV

Researchers observed severe infections in one-quarter of patients with AAV receiving rituximab.

Renal Transplantation Linked to Improved Survival for ESRD Due to Granulomatosis With Polyangiitis

Renal Transplantation Linked to Improved Survival for ESRD Due to Granulomatosis With Polyangiitis

Renal transplantation is associated with a significant decrease in mortality among patients with end-stage renal disease attributed to granulomatosis with polyangiitis.

Individually Tailored vs Fixed-Schedule Rituximab Regimens in ANCA-Associated Vasculitis

Individually Tailored vs Fixed-Schedule Rituximab Regimens in ANCA-Associated Vasculitis

Results of the MAINRITSAN2 trial show that ANCA-associated vasculitides relapse rates did not differ significantly among patients treated with individually tailored vs fixed-schedule rituximab infusion regimens.

Takayasu Arteritis: Efficacy and Safety of Tocilizumab vs Placebo

Takayasu Arteritis: Efficacy and Safety of Tocilizumab vs Placebo

Tocilizumab therapy improves time to relapse in Takayasu arteritis with a favorable safety and tolerability profile.

Large Vessel Vasculitis Imaging: Recommendations for Clinical Practice

Large Vessel Vasculitis Imaging: Recommendations for Clinical Practice

EULAR has released 12 evidence-based recommendations for the use of imaging in the diagnosis and monitoring of large vessel vasculitis, including giant cell arteritis and Takayasu arteritis.

First Treatment for Eosinophilic Granulomatosis With Polyangiitis Approved by FDA

First Treatment for Eosinophilic Granulomatosis With Polyangiitis Approved by FDA

The FDA has expanded the approval of mepolizumab for treating eosinophilic granulomatosis with polyangiitis, which causes vasculitis.

Sign Up for Free e-newsletters